Sanofi is to take on Boehringer Ingelheim's consumer health division ... and is a good fit with its existing business in terms of products and geographies, giving it much increased market share ...

"With this new system, Boehringer Ingelheim is expected to resolve data challenges and latencies and speed up the go-to-market of its products. Thanks to the close collaboration across our teams ...

Boehringer Ingelheim is a biopharmaceutical company active in both ... Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's products and services and the ...

After graduation, (1970's) Dale went to work for what is now called Boehringer Ingelheim for four years ... emphasize quality and performance of the products. MVP's mission since the very ...

The heritage of Boehringer Ingelheim in developing medicines for ... Specifically for COPD, our products have been on the market for more than 40 years. Looking ahead, our aim is to significantly ...

Boehringer Ingelheim will conduct biophysical and structural studies ... technology company dedicated to powering better health through innovative technology products and services, announced today a ...

ZÜRICH--(BUSINESS WIRE)--CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716 ...

Boehringer Ingelheim has taken an option on a family ... that spans both pharmacological and digital therapeutic (DTx) products. Leading the charge for new drug therapies is iclepertin (also ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing ...